Clinical Trial Update: A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pimavanserin for agitation and aggression in Alzheimer's disease has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Pimavanserin (pimavanserin)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Agitation and Aggression in Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-03-09